Fatima Djouadi

Toxicologie, Pharmacologie et Signalisation céllulaire - UMR-S 1124
Université Paris Descartes
45 rue des Saints Pères
75270 Paris Cedex 06

Fax : +33 (0) 1 42 86 38 68

Dr. Fatima DJOUADI

INSERM researcher, DR-INSERM
Inborn mitochondrial diseases : pharmacological therapy and metabolic signaling

fatima.djouadi@-Code to remove to avoid SPAM-inserm.fr
+33 1 42 86 22 19, room P470

Our research work aims I) at the identification of molecules, drugs or natural compounds that will correct inborn mitochondrial disorders (defects in fatty acid oxidation, FAO or the respiratory chain, RC) and II) at the identification of new putative therapeutic targets in diverse signaling pathways. Our research is performed mainly on primary cultures of cells obtained from FAO- or RC-deficient patients who have well characterized mutations which allows the pre-clinical evaluation of candidate compounds in a context of personalized medicine.

After several years dedicated to fundamental research on renal physiology in animal models, Fatima Djouadi, Director of Research in the National Institute of Health and Medical Research (INSERM), now is interested in developing new therapeutic strategies for the correction of inborn mitochondrial disorders. The team privileges hypothesis-driven approaches and developes accurate read-outs/endpoints to identify compounds with therapeutic potential for mitochondrial disorders. In particular, we focus on testing drugs, molecules or natural compounds that are known to activate key factors which are involved in the regulation of mitochondrial energy metabolism.

Our experiments are performed preferentially in cultures of patients’ cells (fibroblasts and myoblasts) which allows the analysis of the pharmacological responses as a function of genotype or mutation in panels of different RC or FAO disorders. Over the past years we have demonstrated, for example, that the correction of several genetic mitochondrial disorders can be achieved by pharmacological stimulation of the PPAR/PGC-1α pathway using bezafibrate, a common hypolipidemic drug, or by the use of resveratrol. The concept of target-based pharmacological therapy has been extensively applied to the treatment of common disorders, but has emerged only recently as a promising approach for the treatment of genetic mitochondrial diseases. In line with this, our future projects will continue to explore new hypothesis-driven approaches for the pharmacological therapy of these disorders.

Training :

Since 2010: Team leader “Inborn mitochondrial disorders: pharmacological therapy and metabolic signaling”. the National Institute of Health and Medical Research (INSERM) U1124 (Director : Pr. Robert Barouki), Faculty of Fundamental and Medical Sciences, University Paris Descartes School of Medicine, Paris, France.

2006: Principal investigator (CR1) in the National Center for Scientific Research (CNRS) UPR 9078 (Director: Pr. Daniel Ricquier), Necker Hospital, University Paris Descartes School of Medicine, Paris, France.

2000: Principal investigator (CR1) at INSERM U393 (Director: Pr. Arnold Munnich) Necker Hospital, University Paris Descartes School of Medicine, Paris, France.

1996: Visiting Scientist (funded by NATO) in the laboratory of Dr. Daniel P. Kelly’s at the Center of Cardiovascular Research, Washington University School of Medicine, St Louis, Missouri, USA.

1994: Research scientist (CR2) in INSERM U319 (Director: Dr Claudie Merlet-Bénichou), University Pierre and Marie Curie, Paris, France.

1991 : Ph.D. in Developmental Physiology, INSERM U319 (Director : Dr. C. Merlet-Benichou), University Pierre and Marie Curie, Paris, France.

Recent Publications